title: Upregulation of nucleobindin expression in human-activated lymphocytes and non-Hodgkin's lymphoma.
abstract: Nucleobindin (Nuc) was originally found to be an enhancement factor of anti-DNA antibody production secreted by a lymphoid cell line derived from a lymphoproliferative MRL/lpr mouse. It has been shown that Nuc has a unique structure containing a DNA- and two calcium-binding domains, and a leucine zipper motif, but its biological roles have not yet been fully elucidated. Expression of Nuc was first studied in human lymphocytes. Expression of Nuc mRNA in normal peripheral blood mononuclear cells was significantly increased upon mitogen stimulation. Anti-human Nuc monoclonal antibody H-1D8 immunoprecipitated Nuc protein in the nuclear extract of Molt-4 cells. Furthermore, in the immunohistochemical staining of tumor specimens from 108 patients with non-Hodgkin's lymphoma (NHL) with H-1D8, H-1D8-positive cells were observed in nearly all cases in varying frequency. According to the Working Formulation, the percentage of cases in which more than 90% of the tumor cells were stained with H-1D8 was 65% in the high grade of the histological malignancy, 54% in the intermediate grade, and 22% in the low grade; however, normal cells surrounding the tumor cells were virtually negative for H-1D8. These results showed that the level of Nuc expression in human lymphocytes reflects the status of activation or proliferation of the cells, thus providing a clue for the further investigation into biological roles of Nuc. In addition, it might be applicable to the clinicopathological estimation of NHL as a novel indicator.
authors.affiliation: School of Allied Health Sciences, Tokyo Medical and Dental University, Japan. tetsuo.kubota.mtec@med.tmd.ac.jp
authors.forename: T
authors.initials: T
authors.lastname: Kubota
authors.forename: M
authors.initials: M
authors.lastname: Miyauchi
authors.forename: K
authors.initials: K
authors.lastname: Miura
authors.forename: G
authors.initials: G
authors.lastname: Hirokawa
authors.forename: A
authors.initials: A
authors.lastname: Awaya
authors.forename: N
authors.initials: N
authors.lastname: Miyasaka
authors.forename: Y
authors.initials: Y
authors.lastname: Kurosawa
authors.forename: Y
authors.initials: Y
authors.lastname: Kanai
authors.forename: K
authors.initials: K
authors.lastname: Maruyama
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal; D015152:Blotting, Northern; D002135:Calcium-Binding Proteins; D002648:Child; D004268:DNA-Binding Proteins / Q000276:immunology / Q000378:metabolism*; D006133:Growth Substances / Q000276:immunology / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000378:metabolism*; D008228:Lymphoma, Non-Hodgkin / Q000378:metabolism*; D009419:Nerve Tissue Proteins; D000080866:Nucleobindins; D011233:Precipitin Tests; D012333:RNA, Messenger / Q000032:analysis; D015854:Up-Regulation
chemical_list: D000911:Antibodies, Monoclonal; D002135:Calcium-Binding Proteins; D004268:DNA-Binding Proteins; D006133:Growth Substances; D009419:Nerve Tissue Proteins; D000080866:Nucleobindins; D012333:RNA, Messenger